Results 141 to 150 of about 3,342 (167)
Pre‐Seasonal Treatment With Recombinant Carrier‐Based Birch Vaccine Improves Birch Pollen Allergy
We conducted a two stage SCIT trial with GNR‐127 containing a recombinant fusion protein consisting of Bet v 1 and Mal d 1‐derived peptides fused to PreS from HBV. Stage 1 identified two safe maximum tolerated doses (40 μg and 80 μg). In the following Stage 2, five preseasonal injections were well tolerated, induced dose‐dependent allergen‐specific IgG,
Musa R. Khaitov +43 more
wiley +1 more source
Metabolic dysfunction‐associated steatohepatitis is the second commonest US indication for liver transplantation but remains largely undiagnosed and untreated. Fibrosis stage is the strongest predictor of major adverse liver outcomes, with decompensation rates and transplant‐free survival diverging sharply between F3 and F4, while cardiovascular ...
Malek Ayoub +2 more
wiley +1 more source
The HLA‐A*11:01 allele is associated with persistent viraemia and advanced liver fibrosis in HDV infection. HLA‐A*11:01 carriers exhibit a reduced T‐cell repertoire, suggesting a narrower T‐cell response to the infection. ABSTRACT Background Hepatitis delta virus (HDV) infection causes the most severe form of viral hepatitis, with highly heterogeneous ...
Maria Francesca Cortese +11 more
wiley +1 more source
Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown +2 more
wiley +1 more source
Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley +1 more source
ABSTRACT Purpose This systematic review and meta‐analysis examines the evidence related to the use of HBV positive kidneys into non‐viremic kidney transplant recipients (KTRs). Methods We searched PubMed and Embase through November 2025 and identified studies of recipients of hepatitis B surface antigen positive (HBsAg+) or viremic kidneys.
Dhruv Ahuja +6 more
wiley +1 more source
Abstract Supplement HIV Glasgow 8–11 November 2026, Glasgow, UK/Virtual
Journal of the International AIDS Society, Volume 29, Issue S6, November 2026.
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The Oncologic Burden of Hepatitis C Virus Infection: A Clinical Perspective
Ca-A Cancer Journal for Clinicians, 2017Felipe Samaniego +2 more
exaly
Hepatitis C Viraemia and Liver Disease in Symptom-Free Individuals With Anti-HCV
Lancet, The, 1992Alfredo Alberti +2 more
exaly
Specificity of Anti-HCV ELISA Assessed by Reactivity to Three Immunodominant HCV Regions
Lancet, The, 1990Louise Ducharme, I K Kuramoto
exaly

